Nebula Research & Development LLC Protagonist Therapeutics, Inc Transaction History
Nebula Research & Development LLC
- $464 Billion
- Q1 2024
A detailed history of Nebula Research & Development LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Nebula Research & Development LLC holds 25,446 shares of PTGX stock, worth $881,703. This represents 0.16% of its overall portfolio holdings.
Number of Shares
25,446
Previous 15,286
66.47%
Holding current value
$881,703
Previous $351 Million
110.02%
% of portfolio
0.16%
Previous 0.11%
Shares
2 transactions
Others Institutions Holding PTGX
# of Institutions
187Shares Held
59.5MCall Options Held
35.7KPut Options Held
72.3K-
Farallon Capital Management LLC San Francisco, CA5.74MShares$199 Million0.77% of portfolio
-
Black Rock Inc. New York, NY5.57MShares$193 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.32MShares$184 Million2.47% of portfolio
-
Bvf Inc San Francisco, CA3.76MShares$130 Million3.25% of portfolio
-
State Street Corp Boston, MA3.27MShares$113 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.7B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...